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ABSTRACT Mucosal immunity is considered important for protection against Clos-
tridium difﬁcile infection (CDI). We show that in hamsters immunized with Bacillus
subtilis spores expressing a carboxy-terminal segment (TcdA26–39) of C. difﬁcile toxin
A, no colonization occurs in protected animals when challenged with C. difﬁcile
strain 630. In contrast, animals immunized with toxoids showed no protection and
remained fully colonized. Along with neutralizing toxins, antibodies to TcdA26–39
(but not to toxoids), whether raised to the recombinant protein or to TcdA26–39 ex-
pressed on the B. subtilis spore surface, cross-react with a number of seemingly un-
related proteins expressed on the vegetative cell surface or spore coat of C. difﬁcile.
These include two dehydrogenases, AdhE1 and LdhA, as well as the CdeC protein
that is present on the spore. Anti-TcdA26–39 mucosal antibodies obtained following
immunization with recombinant B. subtilis spores were able to reduce the adhesion
of C. difﬁcile to mucus-producing intestinal cells. This cross-reaction is intriguing yet
important since it illustrates the importance of mucosal immunity for complete pro-
tection against CDI.
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Clostridium difﬁcile infection (CDI) has emerged as a major public health burden andone of the leading causes of antibiotic-associated diarrhea. Symptoms of disease
are typically mild diarrhea, but in nonimmunocompetent hospital patients, more
severe, and potentially fatal, colitis and toxic megacolon can occur (1–3). Disease is
presumed to result from antibiotic treatment that disrupts the intestinal microbiota,
enabling resident spores of C. difﬁcile to germinate and outgrow. Spores are either
resident in low numbers or acquired from the environment, and dysbiosis provides a
temporary environmental niche enabling C. difﬁcile to proliferate and secrete two
cytotoxins (toxins A and B), resulting in inﬂammation and tissue damage (3, 4). The
spore form of C. difﬁcile plays an important role in this disease, and in hospitals, spores
persist due to shedding from infected patients (5, 6). In murine systems, the transmis-
sion and dissemination of C. difﬁcile spores have been studied in detail, providing a
number of important insights into human disease (7). First, while spores can persist in
the gastrointestinal (GI) tract in a carrier state without symptoms, upon antibiotic
treatment, the number of spores dramatically increases by over 6 logs in as little as 2
days. Second, spores shed in the feces are highly infectious and potentially fatal in mice
with a compromised innate immune system. Antibiotic therapy is the most frequent
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clinical treatment, but recurrence is both common (20% of patients) and potentially
life-threatening (1, 2).
Active vaccination is a dependable approach to providing long-term protection
against primary infection as well as recurrence. Current vaccine approaches have
focused on humoral immunity and neutralization of toxins A and B, which are consid-
ered the primary virulence factors (8, 9). Thus, vaccines currently in clinical evaluation
use parenteral administration of toxoids (A and B) or deﬁned segments of them (10).
These vaccines generate antitoxin IgG, and preclinical studies show protection (11).
While protection against symptoms of CDI would be expected, there is no report of any
effect on bacterial colonization (12). This approach, then, is limited since it does not
address the primary stages of colonization and infection. One of the goals of vaccina-
tion is to eradicate the pathogen, and for CDI, this point is salient since, as mentioned
above, infection results in the shedding of signiﬁcant numbers of spores into the
environment. For hospitals, this presents a signiﬁcant burden for control and contain-
ment, and in addition, there are other concerns. First, C. difﬁcile is known to carry
multiple antibiotic resistance elements, and although not yet documented, the poten-
tial for the acquisition and transfer of resistance genes seems likely (13–15). Second,
animals, including livestock, provide a potent reservoir of C. difﬁcile, and the transfer of
animal-derived strains to humans is assumed to have occurred (16, 17). It is therefore
likely that a vaccine focused only on the neutralization of toxins will have little impact
on the continued evolution and dissemination of this pathogen.
Several lines of evidence show that colonization resistance improves protection
against CDI. First, fecal microbiota transplantation (FMT), where extracts of feces are
administered to patients via enema or nasogastric tube, restores colonization resistance
and provides protection against recurrence (18). Second, nontoxigenic strains (e.g.,
strain NTCD-M3) of C. difﬁcile orally administered to patients prevent recurrence
(19–21). Although the underlying mechanisms are not known, it is assumed that
nontoxigenic strains such as NTCD-M3 transiently colonize the GI tract and presumably
outcompete, or exclude, the pathogenic strain.
An oral vaccine consisting of spores of Bacillus subtilis (named PP108) for the
delivery of a deﬁned segment of toxin A corresponding to the toxin cell-binding
domain (TcdA26–39) has been reported by us (22). These heat-stable spores were
engineered to express TcdA26–39 on their surface, and in immunized animals, they
generated IgG as well as secretory IgA (SIgA), both of which were able to neutralize
toxin A and toxin B. In hamsters, 75% protection against primary CDI was observed, and
animals were fully protected against rechallenge (simulating recurrence).
In this study, we have characterized the B. subtilis spore vaccine in greater detail,
showing that it prevents bacterial colonization in hamsters challenged with C. difﬁcile.
In contrast, animals immunized by injection with toxoids A and B remained fully
colonized. We then demonstrated that antibodies against the TcdA26–39 domain rec-
ognize a number of seemingly unrelated proteins found on vegetative cells and spores
of C. difﬁcile. We further show that anti-TcdA26–39 mucosal IgA can reduce the adhesion
of vegetative C. difﬁcile cells to mucus-producing cells. This ﬁnding is important
because, ﬁrst, it deﬁnes the requirements for the design of efﬁcacious vaccines and,
second, it can, in part, provide a mechanism for colonization resistance.
RESULTS
Oral immunization with PP108 spores prevents colonization by C. difﬁcile.
Spores of B. subtilis strain PP108 were produced according to contract good manufac-
turing practice (cGMP) standards and used to dose hamsters either in the live form or
following formaldehyde inactivation. The dosing strategy involved a combined
sublingual-oral (s.o.) administration of four cycles, after which animals were treated
with clindamycin to disrupt the intestinal microbiota before challenge (intragastrically
[i.g.]) with 100 spores of C. difﬁcile strain 630. Control groups included animals dosed
s.o. with live B. subtilis PY79 spores (identical to PP108 but not presenting the TcdA26–39
antigen), animals dosed intramuscularly (i.m.) with the recombinant TcdA26–39
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(rTcdA26–39) protein, and naive animals. All naive animals and those parenterally
immunized with rTcdA26–39 (P  0.6497) succumbed to CDI and died within 50 h (Fig.
1A). For animals dosed with live PP108 spores, 67% were protected (P  0.0115). For
animals dosed with formaldehyde-inactivated PP108 spores, 17% were protected (P 
0.2528), and for those dosed with live PY79 spores, 33% survived (P  0.0084). Using
s.o. delivery, we obtained similar levels of protection using non-cGMP PP108 spores in
two independent trial experiments (data not shown).
In surviving animals, dosed 7 days later with clindamycin (simulating recur-
rence), there was an absence of colonization (see Fig. S1 in the supplemental
material), in agreement with data from our previous study (22). Anti-TcdA26–39 IgG
responses in serum were measured (Fig. 1B), showing that although high IgG titers
were induced in animals dosed orally with PP108 and parenterally with rTcdA26–39,
protection was restricted to animals immunized with PP108. The formaldehyde-
inactivated PP108 spores gave low IgG titers, indicating that the inactivation method
impaired the immunogenicity of the expressed antigen, correlating with the low level
of protection observed. As would be expected, PY79-dosed animals and naive animals
produced no IgG response. Counts of C. difﬁcile spores (CFU) in feces at 24 h postchal-
lenge showed that in all protected animals, no viable C. difﬁcile bacteria were detect-
able, indicating complete pathogen clearance. In contrast, high counts were present in
all nonprotected animals (Fig. 1C). The levels of toxin A and toxin B in feces of protected
(no toxins) and nonprotected (toxins present) animals were determined (Fig. 1D and E)
and conﬁrmed by using cytotoxicity assays (data not shown). This analysis together
with bacteriological assessments (Fig. 1C) demonstrated the absence of infection
(toxins and CFU) in protected animals. Similarly, for protected animals in which recur-
FIG 1 Mucosal vaccination with PP108 spores. Hamsters (6/group) were immunized by the s.o. route with live (PP108-L) or formalin-
inactivated (PP108-F) PP108 spores, live PY79 spores, or the rTcdA26–39 protein by injection (i.m.). (A) Kaplan-Meier survival estimates after
oral challenge of these animals with 100 spores of C. difﬁcile 630. (B) Anti-TcdA26–39 IgG titers in individual animals from each group 2 days
before challenge. *, P  0.05. (C) Counts of 630 spores in feces at 24 h postchallenge in individual animals. (D and E) Levels of toxin A
(D) and toxin B (E) detected in hamster feces from individual groups. A capture ELISA was used to determine toxin levels, and the presence
of functional toxins was also conﬁrmed by using a cell cytotoxicity assay to measure toxin A (HT29 cells) and toxin B (Vero cells) levels
(data not shown). (F) Analysis of fecal IgA and serum IgG obtained from a separate hamster experiment. In this study, groups (n 5) were
orally dosed with PP108 spores or by injection (i.m.) with rTcdA26–39, with 3/5 hamsters being protected in the PP108-dosed group. i.p.,
intraperitoneal.
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rence was induced, no toxins were present during days 3 to 15 following reinfection
(Fig. S1B and S1C).
To measure SIgA levels in hamster feces, we used a goat anti-mouse secondary
antibody to detect the heavy chain of IgA. Note that commercial secondary antibodies
recognizing hamster SIgA are not currently available, but in our hands, anti-mouse IgA
secondary antibody was suitable for the detection of fecal SIgA, as also reported
previously (23). Using fecal samples taken 7 days after the ﬁnal immunization, we were
unable to detect SIgA. However, in a separate study, we were successful in detecting
fecal IgA sampled 14 days following the ﬁnal immunization (Fig. 1F). For simplicity, we
show these data for animals dosed mucosally either with PP108 spores or by injection
with rTcdA26–39 (Fig. 1F) (regimens were the same as those used in the ﬁrst study). In
this study, 3/5 hamsters dosed with PP108 were protected and exhibited high levels of
TcdA26–39-speciﬁc SIgA as well as IgG. On the other hand, all animals dosed with
rTcdA26–39 and the two unprotected PP108-immunized animals showed no SIgA
responses yet retained high levels of IgG. This demonstrates that protection against
colonization best correlates with mucosal antibody responses.
To support this, we also immunized CD-1 mice with cGMP-compliant PP108 spores
(s.o.) (live and inactivated) together with rTcdA26–39 (parenteral). We then showed that
vaccination with live PP108 spores induced neutralizing SIgA in feces as well as
neutralizing serum IgG speciﬁc for TcdA26–39, in contrast to injection of rTcdA26–39,
which induced neutralizing serum IgG only (Fig. 2).
First, this study demonstrates that protection against CDI correlates with a failure to
colonize the host together with the production of mucosal antibodies rather than
serum IgG. Second, spores of B. subtilis that do not express a C. difﬁcile antigen can
provide a low level of protection against CDI.
Parenteral vaccination with toxoids does not prevent colonization. Hamsters
were given three i.m. injections of toxoids A and B (plus adjuvant) and, together with
a naive group, then challenged (i.g.) with 100 spores of C. difﬁcile strain 630. Compared
to naive animals, symptoms of CDI were delayed, but all animals ultimately succumbed
to infection (Fig. 3A) (P  0.0006). In toxoid-immunized animals, serum IgG levels
speciﬁc to toxins A and B were high (Fig. 3B), but counts of C. difﬁcile spores in feces
at 24 h postchallenge demonstrated that animals were fully colonized with C. difﬁcile
(Fig. 3C) at levels indistinguishable from those in naive animals. Consistent with these
FIG 2 Immune responses in immunized CD-1 mice. Groups (n  6) of CD-1 mice were immunized i.g. with live
spores of PP108 (PP108-L), formaldehyde-inactivated PP108 spores (PP108-F), or live PY79 spores or parenterally
(i.m.) with rTcdA26–39 (5 g/dose). Oral dosing was done by using 5  1010 CFU/dose on days 0, 1, 2, 14, 15, 16,
28, 29, 30, 55, 56, and 57. Parenteral dosing was done on days 0, 14, and 28. Fecal IgA was collected 10 to 15 days
after the ﬁnal immunization, serum IgG was collected 21 days after the ﬁnal immunization (A), and anti-TcdA26–39
titers were determined (B). *, P  0.05. Neutralization endpoint titers are shown above the bars and were
determined as described previously (22).
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observations, toxins A and B were readily detectable in cecum samples of sacriﬁced
animals (Fig. 3D and E).
Antibodies to TcdA26–39 cross-react with proteins associated with vegetative
cells and spores. One explanation for how immunization with PP108 spores prevents
colonization is by blocking the adhesion of the bacterium to the mucosa, a phenom-
enon associated with mucosal IgA and its ability to interfere with the adhesion of
bacteria to the host (24). To accomplish this, we would have to reason that antibodies
resulting from oral immunization of PP108 cross-react with vegetative cells or spores of
C. difﬁcile. Since nonrecombinant spores of PY79 were also able to generate some level
of protection against CDI in the experiments described above, we wondered whether
an antibody raised against B. subtilis spores might recognize C. difﬁcile in either its spore
or its vegetative cell form (Fig. 4). Rabbit IgG polyclonal antibodies (PAbs) raised against
B. subtilis PY79 spores (conﬁrmed in Fig. 4A, lane 4) exhibited no detectable cross-
reactivity with vegetative cells of C. difﬁcile 630 or a nontoxigenic isogenic mutant (Fig.
4A, lanes 3 and 4). However, two bands of about 14 and 30 kDa were detected in 630
spore coats (lane 5). Finally, antispore antibodies failed to recognize the rTcdA26–39
protein (lane 1).
A second intriguing possibility was that antibodies to TcdA26–39 were themselves
able to recognize C. difﬁcile. Using an enzyme-linked immunosorbent assay (ELISA), we
showed that vegetative cells of 630 were recognized by TcdA26–39-speciﬁc IgG raised
in CD-1 mice by injection (Fig. 4B). Although toxins would be secreted, to conﬁrm that
these antibodies were recognizing proteins other than toxin A or toxin B, we showed
a similar recognition of cells of an isogenic mutant carrying insertional mutations in the
tcdA and tcdB genes (encoding toxins A and B) (Fig. 4B). Next, we used a panel of
different antisera to probe either spores (Fig. 4C) or vegetative cells (Fig. 4D) of C.
difﬁcile 630 by an ELISA. Naive serum or antisera raised against C. difﬁcile spores or
vegetative cells (both by parenteral immunization) were used as negative or positive
controls, respectively. Anti-PP108 and anti-TcdA26–39 IgG recognized 630 spores
FIG 3 Parenteral vaccination with toxoids. Hamsters (6/group) were immunized with toxoids A and B using three injections (i.m.) and then
challenged with 100 spores of C. difﬁcile 630. (A) Survival of animals compared to the naive groups. (B) Anti-toxoid A and anti-toxoid B
IgG in immunized groups 2 days before challenge. (C) Counts of 630 spores in feces at 24 h postchallenge in immunized and naive groups.
This experiment was repeated once. (D and E) Levels of toxins A (D) and B (E) detected in cecal samples as determined by a capture ELISA,
together with samples from nonimmunized animals (naive infected). Cell cytotoxicity assays were also used to conﬁrm the presence of
toxins.
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(Fig. 4C) and vegetative cells (Fig. 4D) at levels signiﬁcantly higher than those in naive
animals and at levels similar to those of anti-630 spore or anti-630 vegetative cell PAbs.
Using an ELISA, we observed that anti-PY79 spore PAbs also recognized 630 spores but
not 630 vegetative cells, potentially correlating with data from our Western blot
analysis described above (Fig. 4A). Taken together, data from this analysis show ﬁrst
that antibodies to TcdA26–39, whether raised against the recombinant protein or when
presented on B. subtilis spores (PP108), can recognize both spores and vegetative cells
of C. difﬁcile and second that antibodies to B. subtilis PY79 spores are also able to
recognize C. difﬁcile spores but not vegetative cells.
TcdA26–39-speciﬁc antibodies recognize two dehydrogenases and an exospo-
rial protein. Using PAbs raised in rabbits against recombinant TcdA26–39, we probed
extracts of 630 vegetative cells and proteins extracted from 630 spores by Western
blotting (Fig. 5A). These antibodies recognized a high-molecular-mass protein (100
kDa) present in vegetative cells (Fig. 5A, lane 3). To exclude the possibility that this
protein was either toxin A or toxin B, we showed that the same band was detectable
in an isogenic mutant insertionally inactivated in the tcdA and tcdB genes encoding
toxins A and B, respectively (lane 4). Similarly, the band was also apparent in cells of an
isogenic strain (ΔsigK) that is unable to form spores (lane 5) due to an insertion in the
sigK gene encoding a sporulation-speciﬁc transcription factor (K), conﬁrming that the
band originated from the vegetative cell and not from a contaminating spore. The same
PAbs also recognized a number of bands in extracts of 630 spores running at100, 60,
FIG 4 Anti-TcdA26–39 antibodies recognize C. difﬁcile. (A) Protein extracts were run on SDS-PAGE gels and probed
with rabbit PAbs (1/6,000 dilution) raised against B. subtilis PY79 spores. Lane 1, rTcdA26–39 protein (0.7 to 1 g);
lane 2, spore coat proteins extracted from PY79 spores; lane 3, proteins extracted from C. difﬁcile 630 vegetative
cells; lane 4, extracts of vegetative cells of a toxin A-negative, toxin B-negative mutant; lane 5, spore coat extracts
from 630 spores. (B) Cross-reaction to vegetative cells (vc) of 630 or an isogenic 630 mutant carrying insertions in
the tcdA and tcdB genes (toxin A negative and toxin B negative) by an ELISA. Three murine antisera were used:
naive, anti-TcdA26–39, and anti-C. difﬁcile 630. **, P  0.0018. (C) Identiﬁcation of cross-reactions of different murine
antibodies to spores of C. difﬁcile 630 by an ELISA. Wells of 96-well plates were coated with spores (108
spores/well), and sera (all diluted 1/300) from immunized mice were used for detection by an ELISA. -rA26-39,
anti-TcdA26–39; -CDsp, anti-C. difﬁcile 630 spores. **, P  0.008; *, P  0.0112. (D) Identiﬁcation of cross-reactions
of different murine antibodies to vegetative cells of C. difﬁcile 630 by an ELISA. Wells of 96-well plates were coated
with spores (108 spores/well), and sera (all diluted 1/300) from immunized mice were used for detection by an
ELISA. -rA26-39, anti-TcdA26–39; -CDvc, anti-C. difﬁcile 630 vegetative cells. **, P  0.002.
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50, 40, and 20 kDa (Fig. 5A, lane 6). To exclude the possibility that the spore-associated
proteins were toxin fragments, we probed extracts from spore coats of a toxin-deﬁcient
strain (lane 7). With the exception of the 40-kDa band (which might therefore be toxin
derived), the same polypeptides were recognized. To identify proteins recognized by
anti-TcdA26–39 PAbs, we used mass spectrometry (MS) analysis (see Table S1 in the
supplemental material). In both vegetative cells and spore extracts, the100-kDa band
was identiﬁed as AdhE1 (aldehyde alcohol dehydrogenase), and the 50-kDa spore-
speciﬁc species was identiﬁed as CdeC (25).
When we conducted the same analysis using a PAb to toxoid A, we failed to identify
any of the above-described protein bands using the same extracts as those used for the
anti-TcdA26–39 blots, which were run in parallel (Fig. 5B). The integrity of the antibodies
was conﬁrmed by the recognition of rTcdA26–39 (Fig. 5B, lane 1). High-molecular-mass
bands (140 kDa) were apparent in 630 vegetative cells (lane 3) and the ΔsigK mutant
(lane 5) but were absent in the toxin-deﬁcient mutant (lane 4), indicating that these
bands corresponded to toxin A and possibly also toxin B.
These experiments were repeated with three independent MS analyses. We next
examined mucosal antibodies raised in CD-1 mice that had been immunized (s.o.) with
PP108 spores (Fig. 5C). As expected, fecal IgA reacted with rTcdA26–39 (Fig. 5C, lane 1)
and PY79 spore coat extracts (lane 2). Fecal IgA was also able to detect a 100-kDa
FIG 5 C. difﬁcile proteins recognized by anti-TcdA26–39. Shown are Western blots of proteins probed with rabbit anti-rTcdA26–39 IgG
(1/3,000 dilution) (A), mouse anti-toxoid A IgG (1/5,000 dilution) (B), mouse anti-PP108 IgA (1/200 dilution) (C), and mouse anti-PY79 IgA
(1/200 dilution) (D). SDS-PAGE gels were loaded as follows: lane 1, rTcdA26–39 protein (1 g); lane 2, extracts of B. subtilis (Bs) PY79 spore
coats; lane 3, extracts of C. difﬁcile (Cd) 630 vegetative cells; lane 4, extracts of vegetative cells of a 630 strain deﬁcient in toxin A and toxin
B; lane 5, extracts of vegetative cells of a 630 strain unable to produce the sporulation transcription factor K; lane 6, spore coat protein
extracts from 630 spores; lane 7, spore coat protein extracts from spores deﬁcient in the production of toxin A and toxin B. Molecular mass
markers (in kilodaltons) are shown, together with the identity of known proteins or proteins referred to in the text.
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species in C. difﬁcile 630 vegetative cells (lanes 3 to 5), which was identiﬁed as AdhE1
by using MS. In addition, bands of 30 and 36 kDa were apparent. The upper band was
identiﬁed as R-2-hydroxyisocaproate dehydrogenase (also referred to as lactate dehy-
drogenase [LdhA]). Analysis of spore coat extracts revealed a number of bands of 60,
50, and 40 kDa. MS analysis was used to conﬁrm that these bands were indeed CdeC.
Finally, we used fecal IgA obtained from mice orally immunized with PY79 spores (Fig.
2), and therefore devoid of TcdA26–39, to probe extracts (Fig. 5D). These antibodies
recognized coat protein extracts from PY79 spores (Fig. 5D, lane 2) but not rTcdA26–39
(lane 1). These antibodies also recognized cross-reacting bands of about 35 and 40 kDa
in vegetative cell extracts (lanes 3 to 5), with the upper band corresponding to LdhA.
The 100-kDa AdhE1 band was not detected by using these antibodies, conﬁrming that
this protein was uniquely recognized by anti-TcdA26–39 PAbs.
To conﬁrm the identities of some of the principal proteins recognized by anti-
TcdA26–39, we used two approaches. First, we cloned and expressed the LdhA, AdhE1,
and CdeC proteins in Escherichia coli as His-tagged polypeptides. For rLdhA, the
full-length protein was expressed, while for rAdhE1 and rCdeC, sequences encoding
N-terminal segments of each protein were cloned. Anti-TcdA26–39 PAbs were able to
recognize each of these recombinant proteins as well as rTcdA26–39 (Fig. 6A). In the case
of rAdhE1, a molecular mass of 47 kDa was detected because only the N-terminal half
of AdhE1 was cloned and expressed, while for rCdeC, only a small N-terminal domain
(12 kDa) could be cloned. The appearance of multiple CdeC species of higher
molecular masses is most probably due to extensive covalent cross-linking found in this
cysteine-rich protein, as reported previously (25).
The anti-TcdA26–39 antibodies were raised to a recombinant His-tagged TcdA26–39
polypeptide, so it is formally possible that recognition arose due to antibodies recog-
nizing the C-terminal polyhistidine moiety. Therefore, we used a more stringent ap-
proach and made ClosTron insertional mutants for each gene. Using ΔcdeC and
630Δerm spores, we probed coat proteins extracted from spores (Fig. 6B). In wild-type
extracts, principal species of about 35, 50, and 100 kDa were observed, in agreement
with data from previous studies showing that CdeC is present in multimeric forms in
spores (25). In contrast, in the ΔcdeCmutant, with the exception of the 100-kDa species,
these bands were absent, conﬁrming that the bands of 100 kDa were indeed CdeC.
The 100-kDa species that was recognized by anti-TcdA26–39 PAbs was identiﬁed as
AdhE1 (26).
Antibodies to TcdA26–39 reduce adhesion of C. difﬁcile to mucus-producing
HT29-MTX cells. The human intestinal cell line HT29-MTX, derived from HT29, is a
mucus-secreting cell line that contains differentiated goblet cells that secrete low levels
of MUC2 mucins typically found in the small and large intestines (27). Cells grown for
14 days and conﬁrmed to produce mucus by alcian blue staining were inoculated with
vegetative cells or spores of strain 630 with or without adsorption with fecal IgA or
FIG 6 Veriﬁcation of cross-reacting proteins. (A) Recombinant proteins identiﬁed by anti-TcdA26–39.
Approximately 1 g of puriﬁed protein was run per lane and probed with antibodies at a dilution of
1/4,000. (B) Bands recognized in proteins extracted from spores of the wild type (630Δerm) and a ΔcdeC
mutant probed with anti-TcdA26–39 (1/4,000 dilution). Molecular masses (in kilodaltons) are indicated.
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serum IgG obtained from CD-1 mice immunized (s.o.) with PP108 or PY79 spores (Fig.
7A). Naive IgA was capable of reducing adhesion, which is consistent with data from
other studies showing that innate, nonspeciﬁc SIgA by itself has the ability to interfere
with the attachment of cells to mucus (28). However, compared to naive cells, anti-
PP108 fecal IgA signiﬁcantly reduced the adhesion of vegetative cells to HT29-MTX
cells. However, fecal IgA from animals immunized with PY79 spores did not show any
reduction in adhesion compared to naive IgA. In contrast, anti-PP108 IgG showed no
signiﬁcant reduction in adhesion compared to naive IgG. When we conducted the same
analysis on 630 spores, anti-PP108 IgA showed no effect on adhesion compared to
anti-PY79 IgA or naive IgA, as was also the case with anti-PP108 IgG (Fig. 7B).
DISCUSSION
The oral PP108 vaccine utilizing bacterial spores for the display of a carboxy-terminal
domain (TcdA26–39) of toxin A was reported previously (22). The key ﬁndings, then,
were that (i) oral delivery generated mucosal as well as systemic humoral neutralizing
responses, but only mucosal antibodies correlated with protection; (ii) antibodies to the
TcdA26–39 domain cross-reacted with toxin B, presumably by virtue of shared homology
between the C-terminal domains of toxins A and B; and (iii) immunization with
nonrecombinant spores provided evidence of protection. Here, we show that the PP108
spore vaccine is also able to inhibit the colonization of hamsters with C. difﬁcile.
Colonization in this case was deﬁned as the absence of toxins as well as viable spores
in the feces. We assume that the complete protection observed here occurs because
TcdA26–39-speciﬁc IgA prevents the early stages of attachment of C. difﬁcile vegetative
cells to the mucosal epithelium. These initial stages of colonization are presumably
critical to the infection process and prevent the subsequent establishment of the
pathogen at the mucosal barrier, e.g., in the creation of bioﬁlms (29). Therefore, this
correlate of protection is particularly important and more meaningful than measure-
ments of toxin levels alone.
Most intriguing was that in studies using the same hamster model of infection,
parenteral immunization of toxoids A and B failed to confer protection, even though
high levels of IgG were found in serum. It should be noted that, as far as we are aware,
most vaccination studies using hamsters have used the VPI 10463 strain, since it is
assumed to be highly toxigenic. Although not reported here, we also evaluated, in
parallel, toxoid-immunized hamsters challenged with spores of VPI 10463 and obtained
FIG 7 Mucosal antibodies to TcdA26–39 reduce adhesion of vegetative cells to mucus-producing HT29-MTX cells.
HT29-MTX cells were grown for 14 days, and the production of mucus was conﬁrmed. Vegetative cells (A) or spores
(B) of C. difﬁcile 630 were pretreated with either serum IgG or fecal IgA (1/300 dilution) obtained from CD-1 mice
immunized s.o. with live PP108 spores or live PY79 spores, as shown in Fig. 2. Adhesion to cells was expressed as
a percentage of untreated cells or spores run in parallel. Adhesion of 100% equates to the number of cells or spores
adhering to HT29-MTX cells without pretreatment and in parallel. The experiment was repeated two times, with
similar ﬁndings. *, P  0.05.
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only 25% protection. Our ﬁndings suggest that, at least in hamsters, 630 either is more
infectious or produces more severe infection.
The single most important ﬁnding from this work is that antibodies to the TcdA26–39
domain recognize not only TcdA26–39 but also other peptide sequences. First, and as
discovered previously (22), they recognize the C terminus of toxin B, and second, they
react with a number of other proteins present in vegetative cells or spores of C. difﬁcile,
including AdhE1, LdhA, and CdeC. Intriguingly, we were unable to identify any mean-
ingful homology in amino acid sequences between TcdA26–39 and AdhE1, LdhA, and
CdeC, although both AdhE1 and LdhA share some homology in their secondary
structures (30). The ability of TcdA26–39 antibodies to recognize additional C. difﬁcile
proteins could therefore provide immunized animals with the ability to recognize
vegetative cells and spores of C. difﬁcile during infection as well as neutralize toxins,
explaining the complete absence of colonization in protected animals.
Mucosal antibodies consist primarily of SIgA, but opsonizing IgG could potentially
also be present. SIgA is well known for its ability to interfere with the earliest steps of
infection by blocking toxins and preventing the adhesion of pathogens to the mucosal
epithelium (31). For example, SIgA has been shown to sterically hinder the interaction
of cholera toxin with epithelial cells (32). The two dehydrogenases recognized by
TcdA26–39-speciﬁc antibodies, AdhE1 and LdhA, could also have potential roles in
virulence. In Listeria monocytogenes, an aldehyde alcohol dehydrogenase is a house-
keeping enzyme but is also a surface-exposed adhesin commonly referred to as LAP
(Listeria adhesion protein) (33). In C. difﬁcile, LdhA participates in a biosynthetic path-
way, another member of which, HadA, has been found to be associated with bioﬁlms,
a key attribute linked to colonization (34). Both AdhE1 and LdhA may or may not be
involved in virulence, and they may or may not be surface exposed, but what is
important here is the demonstration that mucosal antibodies can block C. difﬁcile
colonization. It is also likely that there are other targets recognized by TcdA26–39-
speciﬁc antibodies, so the key points are that (i) cross-recognition of cell proteins by
mucosal TcdA26–39-speciﬁc antibodies can explain how the PP108 vaccine prevents
both colonization and cytotoxicity and (ii) mucosal immunity is required for the
prevention of C. difﬁcile colonization. Since the TcdA26–39 domain is part of toxin A, it
is prima facie surprising that immunization with toxoids fails to generate cross-reactive
antibodies. The explanation, though, may simply be that the tertiary structure of toxoid
A fails to generate sufﬁcient TcdA26–39-speciﬁc antibodies in both quantity and avidity
for cross-reaction to C. difﬁcile vegetative cells or that it may be of the wrong isotype.
What is shown here is that mucosal antibodies targeting one or more antigens (or
epitopes) block the interaction of the pathogen with the host and, as a result, prevent
colonization. This ﬁnding suggests that to prevent CDI as well as relapse, an approach
that addresses colonization must be considered (12). It is possible, then, that C. difﬁcile
colonization is particularly sensitive to interference, and this could be a factor in how
other “nontoxin” approaches appear to work. For example, in this work, it is shown that
the administration of nonrecombinant PY79 spores provided some level of protection,
and for these animals, no colonization was present. For both rabbit anti-PY79 IgG and
mouse anti-PY79 fecal IgA, some cross-recognition of C. difﬁcile proteins was apparent,
including the LdhA protein, which is supported by data from previous studies showing
that oral dosing with B. subtilis probiotic spores reduces symptoms of CDI (35).
However, there is no signiﬁcant sequence homology between B. subtilis Ldh and that
of C. difﬁcile.
We wonder whether immune exclusion may, in part, explain the ability of nontoxi-
genic cells of C. difﬁcile to suppress symptoms of CDI. Previous studies using pretreat-
ment of animals with nontoxigenic strains of C. difﬁcile demonstrated that the non-
toxigenic strain can colonize the GI tract, and following challenge 40 to 60 days later,
animals were fully protected (21). It may therefore be of interest to investigate SIgA
produced in animals dosed with atoxigenic C. difﬁcile to determine whether it plays any
role in preventing colonization. Finally, the ability to prevent adhesion using mucosal
antibodies raises the possibility of developing speciﬁc immunity-based antiadhesion
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therapies (36). In light of the studies described here, we believe that for complete
protection against CDI, strategies that elicit mucosal immunity must be considered.
MATERIALS AND METHODS
Methods relating to the production of spores, antibodies, mutant constructions, and analysis of
immune responses are described in the supplemental material.
Strains. PP108 is a recombinant strain of B. subtilis that expresses a carboxy-terminal domain of C.
difﬁcile toxin A (referred to here as TcdA26–39 or A26-39 and carrying repeats spanning positions 26 to 39
[as deﬁned in reference 37] and residues Ser2388 to Pro2706) as a chimeric fusion to two individual B.
subtilis spore coat proteins, CotB and CotC (22). PY79 is a nonrecombinant strain of B. subtilis and isogenic
to PP108. C. difﬁcile strain 630 (ribotype 012; toxin A positive and toxin B positive [38]) was used for
challenge studies. A strain isogenic to 630 containing ClosTron insertional mutations in the tcdA (toxin
A) and tcdB (toxin B) genes was obtained from N. Minton (9). ClosTron mutants isogenic to 630 and
carrying insertions in the sigK gene (encoding sigma factor K of strain JP051) or the cdeC genes (strain
SH2000) were made in this study (see methods in the supplemental material).
Immunizations. Golden Syrian hamsters (aged 5 to 6 weeks and weighing 120 to 130 g) were dosed
(n  6) with live or formaldehyde-inactivated PP108 spores and live PY79 spores (5  1010 spores/dose)
in 4 dosing cycles (cycle 1, days 1, 2, and 3; cycle 2, days 14, 15, and 16; cycle 3, days 28, 29, and 30; cycle
4, days 42, 43, and 44). Dosing was done by utilizing combined s.o. administration, where the animals
received 50 l by sublingual administration and 150 l via oral gavage. For sublingual administration,
animals were anesthetized (isoﬂurane), and the test substance was allowed to adsorb for 30 min.
Additional groups included those receiving the rTcdA26–39 protein (10 g/dose) by injection (i.m.) on
days 1, 14, and 28. For immunization with toxoids, animals were given three i.m. injections (days 1, 14,
and 28) of both toxoid A and toxoid B (Native Antigen Company) at 5 g/dose, resuspended in an alum
adjuvant in saline buffer. All animal work was performed under UK Home Ofﬁce project license PPL
70/8276.
Challenge studies. Preliminary challenge experiments using nonimmunized hamsters were ﬁrst
conducted to conﬁrm the infectious dose of 630 spores. The challenge commenced 14 days after the last
immunization and when animals were transferred to individual IVCs (independently ventilated cages)
and then treated with clindamycin (clindamycin-2-phosphate at 30 mg/kg body weight; Sigma). Twelve
hours after antibiotic treatment, animals were dosed i.g. with 100 spores of strain 630. Animals were
transferred to new cages every 2 days and monitored every 3 h until clear symptoms developed, after
which infected animals were killed and considered unprotected. Symptoms were deﬁned as “wet tail,”
where animals developed watery diarrhea, lethargy, and irritability and refused food.
Colonization. To determine colonization, feces was collected at 2 days postchallenge, homogenized
in 70% ethanol, incubated overnight, serially diluted in sterile water, and plated onto ChromID plates
(bioMérieux). Plates were incubated anaerobically (37°C) for 2 days before counting.
Immunological analysis. (i) Mice. Basic methodologies for immunological analysis of mice were
described previously (22). Levels of serum anti-TcdA26–39 IgG and fecal IgA from CD-1 mice were
determined by an indirect ELISA. Greiner 96-well plates were coated with the puriﬁed rTcdA26–39 (2
g/ml) protein in phosphate-buffered saline (PBS) overnight at room temperature (RT). After this, the
plates were blocked for 1 h at 37°C with 2% bovine serum albumin (BSA), and 2-fold serially diluted
samples were added at a starting dilution of 1/50 in diluent buffer (0.01 M PBS [pH 7.4], 1% BSA, 0.05%
Tween 20). Replicate samples were used together with a negative control (preimmune or naive serum).
Plates were incubated for 2 h at 30°C before the addition of the appropriate horseradish peroxidase
(HRP)-conjugated anti-mouse antibodies in diluent buffer. Plates were incubated for 1 h at RT and then
developed by using the 3,3=,5,5=-tetramethylbenzidine (TMB) substrate. Reactions were stopped by using
2 M H2SO4, and optical densities (ODs) were read at 450 nm. Dilution curves were created for each
sample, and endpoint titers for each speciﬁc antibody were estimated as the maximum dilution of serum
giving an absorbance reading of 0.1 over the ODs of naive samples.
(ii) Hamsters. (a) Serum IgG. Blood was withdrawn from the saphenous vein 2 days before
challenge. Greiner Bio One 96-well high-binding plates were coated with proteins (50 l/well). For
anti-TcdA26–39 responses, plates were coated with the rTcdA26–39 protein (2 g/ml) in PBS, while for
antitoxin responses, plates were coated with toxins A and B (2 g/ml; Sigma). Plates were left overnight
at 4°C and then blocked for 1 h with 2% BSA diluted in PBS. Samples were loaded using 2-fold dilutions
(diluent containing PBS, 0.05% Tween 20, and 1% BSA). The starting dilution for serum samples was
1/100. Samples were incubated for 2 h at RT before incubation with HRP-conjugated goat anti-hamster
IgG antibodies (1/7,500) in diluent buffer (PBS, 1% BSA, 0.05% Tween 20). Plates were incubated for 1 h
at RT and developed by using the TMB substrate (BioLegend). Reactions were stopped by using 2 M
H2SO4, and the OD was read at 450 nm. Dilution curves were determined for each sample, and the
endpoint titer for each sample was estimated according to the ODs of naive samples.
(b) Fecal IgA. Fecal samples were collected 2 days before challenge and broken up by using wooden
sticks in extraction buffer at an approximate ratio of 1:5 (feces to buffer). The extraction buffer was made
up in PBS containing 2% (vol/vol) fetal calf serum, penicillin-streptomycin (10 ml/liter) (catalog number
P4333; Sigma), and Pierce protease inhibitor tablets (catalog number 88265; Thermo). Suspensions were
shaken gently at 4°C for 4 h and then centrifuged (13,000 rpm for 15 min in a benchtop Microfuge), and
the supernatant was retained. An indirect ELISA was performed as described above for serum but with
the following modiﬁcations: (i) the starting dilution was 1/5 or 1/10, and incubation was done at 30°C for
2 h, and (ii) a conjugated mouse IgA-HRP antibody (Sigma) was used at a 1/1,000 dilution at RT for 1 h.
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Identiﬁcation of proteins cross-reacting with anti-TcdA26–39. See the methods in the supplemen-
tal material for the construction of ClosTron mutants. rAdhE1, rLdhA, and rCdeC were puriﬁed by using
Akta chromatography of His-tagged proteins. E. coli expression clones utilized pET28b vectors containing
segments of cdeC, adhE1, and ldhA (see Table S1 in the supplemental material) as follows: Met1-Phe105
for cdeC (C-terminal His tag, 12.1 kDa), Lys2-Asn332 for ldhA (N-terminal His tag, 36.3 kDa), and
Glu2-Gly420 for adhE1 (N-terminal 45.2 kDa).
Statistics. The Mantel-Cox test was used for data in Fig. 1A and 3A, the Mann-Whitney test was used
for data in Fig. 1B to D and 2, a paired t test was used for data in Fig. 4C and D, and an unpaired t test
was used for data in Fig. 7.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
IAI.01060-16.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.1 MB.
SUPPLEMENTAL FILE 2, PDF ﬁle, 0.1 MB.
SUPPLEMENTAL FILE 3, PDF ﬁle, 0.1 MB.
ACKNOWLEDGMENTS
This work was supported by a grant (HEALTH-F3-2013-601810) from the European
Union to S.M.C., J.K., and A.V.B. and a grant from the MRC (MR/K015354/1) to S.M.C.
We thank N. Josh for technical assistance.
REFERENCES
1. Kelly CP, LaMont JT. 2008. Clostridium difﬁcile—more difﬁcult than ever.
N Engl J Med 359:1932–1940. https://doi.org/10.1056/NEJMra0707500.
2. Dobson G, Hickey C, Trinder J. 2003. Clostridium difﬁcile colitis causing
toxic megacolon, severe sepsis and multiple organ dysfunction syn-
drome. Intensive Care Med 29:1030. https://doi.org/10.1007/s00134-003
-1754-7.
3. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. 2016. Clostridium
difﬁcile infection. Nat Rev Dis Primers 2:16020. https://doi.org/10.1038/
nrdp.2016.20.
4. Shen A. 2012. Clostridium difﬁcile toxins: mediators of inﬂammation. J
Innate Immun 4:149–158. https://doi.org/10.1159/000332946.
5. Gerding DN, Muto CA, Owens RC, Jr. 2008. Measures to control and
prevent Clostridium difﬁcile infection. Clin Infect Dis 46(Suppl 1):S43–S49.
https://doi.org/10.1086/521861.
6. Martin JS, Monaghan TM, Wilcox MH. 2016. Clostridium difﬁcile infection:
epidemiology, diagnosis and understanding transmission. Nat Rev Gastro-
enterol Hepatol 13:206–216. https://doi.org/10.1038/nrgastro.2016.25.
7. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N,
Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW,
Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difﬁcile
carrier mice triggers a supershedder state, spore-mediated transmission,
and severe disease in immunocompromised hosts. Infect Immun 77:
3661–3669. https://doi.org/10.1128/IAI.00558-09.
8. Kelly CP, Kyne L. 2011. The host immune response to Clostridium difﬁcile.
J Med Microbiol 60:1070–1079. https://doi.org/10.1099/jmm.0.030015-0.
9. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010.
The role of toxin A and toxin B in Clostridium difﬁcile infection. Nature
467:711–713. https://doi.org/10.1038/nature09397.
10. Ghose C, Kelly CP. 2015. The prospect for vaccines to prevent Clostridium
difﬁcile infection. Infect Dis Clin North Am 29:145–162. https://doi.org/
10.1016/j.idc.2014.11.013.
11. Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Klean-
thous H. 2013. Systemic antibody responses induced by a two-
component Clostridium difﬁcile toxoid vaccine protect against C. difﬁcile-
associated disease in hamsters. J Med Microbiol 62:1394–1404. https://
doi.org/10.1099/jmm.0.056796-0.
12. Kociolek LK, Gerding DN. 2016. Breakthroughs in the treatment and
prevention of Clostridium difﬁcile infection. Nat Rev Gastroenterol Hepa-
tol 13:150–160. https://doi.org/10.1038/nrgastro.2015.220.
13. Spigaglia P, Barbanti F, Mastrantonio P, European Study Group on
Clostridium difﬁcile. 2011. Multidrug resistance in European Clostridium
difﬁcile clinical isolates. J Antimicrob Chemother 66:2227–2234. https://
doi.org/10.1093/jac/dkr292.
14. Tenover FC, Tickler IA, Persing DH. 2012. Antimicrobial-resistant strains
of Clostridium difﬁcile from North America. Antimicrob Agents Che-
mother 56:2929–2932. https://doi.org/10.1128/AAC.00220-12.
15. Spigaglia P. 2016. Recent advances in the understanding of antibiotic
resistance in Clostridium difﬁcile infection. Ther Adv Infect Dis 3:23–42.
https://doi.org/10.1177/2049936115622891.
16. Debast SB, van Leengoed LA, Goorhuis A, Harmanus C, Kuijper EJ,
Bergwerff AA. 2009. Clostridium difﬁcile PCR ribotype 078 toxinotype V
found in diarrhoeal pigs identical to isolates from affected humans.
Environ Microbiol 11:505–511. https://doi.org/10.1111/j.1462-2920.2008
.01790.x.
17. Rupnik M, Widmer A, Zimmermann O, Eckert C, Barbut F. 2008. Clostrid-
ium difﬁcile toxinotype V, ribotype 078, in animals and humans. J Clin
Microbiol 46:2146. https://doi.org/10.1128/JCM.00598-08.
18. Tvede M, Rask-Madsen J. 1989. Bacteriotherapy for chronic relapsing
Clostridium difﬁcile diarrhoea in six patients. Lancet i:1156–1160.
19. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van
Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. 2015.
Administration of spores of nontoxigenic Clostridium difﬁcile strain M3
for prevention of recurrent C. difﬁcile infection: a randomized clinical
trial. JAMA 313:1719–1727. https://doi.org/10.1001/jama.2015.3725.
20. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. 2012.
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clos-
tridium difﬁcile strain M3, in healthy subjects. Antimicrob Agents Chemother
56:5224–5229. https://doi.org/10.1128/AAC.00913-12.
21. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colo-
nization for the prevention of Clostridium difﬁcile disease in hamsters. J
Infect Dis 186:1781–1789. https://doi.org/10.1086/345676.
22. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J,
Fairweather NF, Cutting SM. 2011. Immunization with Bacillus spores
expressing toxin A peptide repeats protects against infection with Clos-
tridium difﬁcile strains producing toxins A and B. Infect Immun 79:
2295–2302. https://doi.org/10.1128/IAI.00130-11.
23. Bungiro RD, Jr, Sun T, Harrison LM, Shoemaker CB, Cappello M. 2008.
Mucosal antibody responses in experimental hookworm infection. Par-
asite Immunol 30:293–303. https://doi.org/10.1111/j.1365-3024.2008
.01023.x.
24. Corthesy B. 2009. Secretory immunoglobulin A: well beyond immune
exclusion at mucosal surfaces. Immunopharmacol Immunotoxicol 31:
174–179. https://doi.org/10.1080/08923970802438441.
25. Barra-Carrasco J, Olguin-Araneda V, Plaza-Garrido A, Miranda-Cardenas
C, Cofre-Araneda G, Pizarro-Guajardo M, Sarker MR, Paredes-Sabja D.
2013. The Clostridium difﬁcile exosporium cysteine (CdeC)-rich protein is
required for exosporium morphogenesis and coat assembly. J Bacteriol
195:3863–3875. https://doi.org/10.1128/JB.00369-13.
26. Redmond C, Baillie LW, Hibbs S, Moir AJ, Moir A. 2004. Identiﬁcation of
Hong et al. Infection and Immunity
April 2017 Volume 85 Issue 4 e01060-16 iai.asm.org 12
 o
n
 M
arch 23, 2017 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
proteins in the exosporium of Bacillus anthracis. Microbiology 150:
355–363. https://doi.org/10.1099/mic.0.26681-0.
27. Lesufﬂeur T, Barbat A, Dussaulx E, Zweibaum A. 1990. Growth adaptation
to methotrexate of HT-29 human colon carcinoma cells is associated
with their ability to differentiate into columnar absorptive and mucus-
secreting cells. Cancer Res 50:6334–6343.
28. Wijburg OL, Uren TK, Simpfendorfer K, Johansen FE, Brandtzaeg P,
Strugnell RA. 2006. Innate secretory antibodies protect against natural
Salmonella typhimurium infection. J Exp Med 203:21–26. https://doi.org/
10.1084/jem.20052093.
29. Dawson LF, Valiente E, Faulds-Pain A, Donahue EH, Wren BW. 2012. Char-
acterisation of Clostridium difﬁcile bioﬁlm formation, a role for Spo0A. PLoS
One 7:e50527. https://doi.org/10.1371/journal.pone.0050527.
30. Kutzenko AS, Lamzin VS, Popov VO. 1998. Conserved supersecondary
structural motif in NAD-dependent dehydrogenases. FEBS Lett 423:
105–109. https://doi.org/10.1016/S0014-5793(98)00074-X.
31. Mantis NJ, Rol N, Corthesy B. 2011. Secretory IgA’s complex roles in
immunity and mucosal homeostasis in the gut. Mucosal Immunol
4:603–611. https://doi.org/10.1038/mi.2011.41.
32. Apter FM, Michetti P, Winner LS, III, Mack JA, Mekalanos JJ, Neutra MR.
1993. Analysis of the roles of antilipopolysaccharide and anti-cholera
toxin immunoglobulin A (IgA) antibodies in protection against Vibrio
cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
Infect Immun 61:5279–5285.
33. Jagadeesan B, Koo OK, Kim KP, Burkholder KM, Mishra KK, Aroonnual A,
Bhunia AK. 2010. LAP, an alcohol acetaldehyde dehydrogenase enzyme
in Listeria, promotes bacterial adhesion to enterocyte-like Caco-2 cells
only in pathogenic species. Microbiology 156:2782–2795. https://
doi.org/10.1099/mic.0.036509-0.
34. Semenyuk EG, LaningML, Foley J, Johnston PF, Knight KL, Gerding DN, Driks
A. 2014. Spore formation and toxin production in Clostridium difﬁcile bio-
ﬁlms. PLoS One 9:e87757. https://doi.org/10.1371/journal.pone.0087757.
35. Colenutt C, Cutting SM. 2014. Use of Bacillus subtilis PXN21 spores for
suppression of Clostridium difﬁcile infection symptoms in a murine
model. FEMS Microbiol Lett 358:154–161. https://doi.org/10.1111/1574
-6968.12468.
36. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. 2014. Review article:
anti-adhesion therapies for inﬂammatory bowel disease. Aliment Phar-
macol Ther 39:579–594. https://doi.org/10.1111/apt.12639.
37. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson
JL. 1990. Molecular characterization of the Clostridium difﬁcile toxin A
gene. Infect Immun 58:480–488.
38. Wust J, Sullivan NM, Hardegger U, Wilkins TD. 1982. Investigation of an
outbreak of antibiotic-associated colitis by various typing methods. J
Clin Microbiol 16:1096–1101.
Preventing C. difﬁcile Colonization Infection and Immunity
April 2017 Volume 85 Issue 4 e01060-16 iai.asm.org 13
 o
n
 M
arch 23, 2017 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
